RELATED CONTENT
NEWS
- EU approval for Bydureon despite US setbacks
- EMA confirms Champix' positive benefit-risk balance, but will review data in September
- Betanis, Tradjenta and Onbrez priced and set for launch in Japan
- AMAG, Allos to merge – but will it really bring sales synergies for Feraheme, Folotyn?

